Autoinjectors may be suitable for projects that require: Fixed-dose delivery Fewer user steps Hidden needle design Push-button or push-on-skin activation A more guided home-use experience A strong focus on patient confidence Differentiated premium device positioning However, an autoinjector is not always the best answer
Moreover, the intestines produce insulin and stop glucagon release
Scheduling is easy and they are super accommodating
The New Nomad PRO now comes with a built-in temperature display
102 5.1.1.1 GROWING DEMAND FOR SELF-INJECTION DEVICES 5.1.1.2 ADVANCEMENTS IN DRUG DELIVERY TECHNOLOGIES 5.1.1.3 RISING PREVALENCE OF CHRONIC DISEASES 5.1.1.4 GROWING ADOPTION OF BIOLOGICS AND BIOSIMILARS 5.1.2.1 INFECTIONS ASSOCIATED WITH NEEDLESTICK INJURIES 5.1.2.2 STRINGENT GOVERNMENT REGULATIONS 5.1.3.1 DEVELOPMENT OF NOVEL DRUG DELIVERY SYSTEMS 5.1.3.2 GROWING PREFERENCE FOR HOME-BASED CARE DEVICES 5.1.3.3 GROWTH OPPORTUNITIES IN EMERGING ECONOMIES 5.1.4.1 ALTERNATIVE METHODS OF DRUG DELIVERY 5.1.4.2 COMPLEXITIES IN DEVELOPING WEARABLE DRUG DELIVERY SYSTEMS 5.2.1 REUSABLE DRUG DELIVERY DEVICES 5.2.2 PREFILLED BIOLOGICS 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER 5.4.1.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY DEVICE TYPE 5.4.1.2 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PEN INJECTORS 5.4.2 AVERAGE SELLING PRICE TREND, BY REGION 5.4.2.1 AVERAGE SELLING PRICE TREND OF PEN INJECTORS, BY REGION 5.4.2.2 AVERAGE SELLING PRICE TREND OF NEEDLE-FREE INJECTORS, BY REGION 5.4.2.3 AVERAGE SELLING PRICE TREND OF AUTOINJECTORS, BY REGION 5.4.2.4 AVERAGE SELLING PRICE TREND OF WEARABLE INJECTORS, BY REGION 5.5.1 RESEARCH & PRODUCT DEVELOPMENT 5.5.2 RAW MATERIAL PROCUREMENT 5.5.4 MARKETING, SALES & DISTRIBUTION, AND AFTER-SALES SERVICES 5.6 SUPPLY CHAIN ANALYSIS 5.8 INVESTMENT AND FUNDING SCENARIO 5.9.1.1 AUTOINJECTORS AND SMART INJECTION DEVICES 5.9.1.2 NEEDLE-FREE INJECTION SYSTEMS AND MICRONEEDLE PATCHES 5.9.1.3 WEARABLE INJECTORS FOR HIGH-VOLUME DELIVERY 5.9.2 COMPLEMENTARY TECHNOLOGIES 5.9.2.2 BIODEGRADABLE POLYMERS 5.9.3 ADJACENT TECHNOLOGIES 5.9.3.1 ARTIFICIAL INTELLIGENCE AND DIGITAL THERAPEUTICS 5.9.3.2 ALTERNATIVE ROUTES OF ADMINISTRATION 5.10.1 PATENT PUBLICATION TRENDS FOR INJECTABLE DRUG DELIVERY 5.10.2 JURISDICTION AND TOP APPLICANT ANALYSIS 5.11.1 TRADE DATA FOR HS CODE 901890 5.11.2 TRADE DATA FOR HS CODE 90183100 5.12 KEY CONFERENCES AND EVENTS, 20252026 5.14 REGULATORY LANDSCAPE 5.14.1 REGULATORY ANALYSIS 5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 5.15 PORTERS FIVE FORCES ANALYSIS 5.15.1 BARGAINING POWER OF SUPPLIERS 5.15.2 BARGAINING POWER OF BUYERS 5.15.3 THREAT OF NEW ENTRANTS 5.15.4 THREAT OF SUBSTITUTES 5.15.5 INTENSITY OF COMPETITIVE RIVALRY 5.16 KEY STAKEHOLDERS AND BUYING CRITERIA 5.16.2.1 BUYING CRITERIA FOR INJECTABLE DRUG DELIVERY DEVICES 5.16.2.2 BUYING CRITERIA FOR INJECTABLE DRUG DELIVERY DEVICES WITH FORMULATIONS 5.18 REIMBURSEMENT ANALYSIS 5.19 UNMET NEEDS/END-USER EXPECTATIONS 5.20 IMPACT OF AI/GEN AI IN INJECTABLE DRUG DELIVERY MARKET 5.20.2 MARKET POTENTIAL OF AI IN INJECTABLE DRUG DELIVERY ECOSYSTEM 5.20.4 KEY COMPANIES IMPLEMENTING AI IN INJECTABLE DRUG DELIVERY DEVICES 5.20.5 FUTURE OF GEN AI IN INJECTABLE DRUG DELIVERY ECOSYSTEM 5.21 IMPACT OF 2025 US TARIFF 5.21.3 PRICE IMPACT ANALYSIS 5.21.4 IMPACT ON COUNTRY/REGION 5.21.5 IMPACT ON END-USE INDUSTRIES 6 INJECTABLE DRUG DELIVERY, BY PRODUCT Market Size & Growth Rate Forecast Analysis to 2030 in USD Billion and Units | 138 Data Tables 159 6.2.1 CONVENTIONAL INJECTION DEVICES 6.2.1.1.1 GLASS INJECTABLE DEVICES 6.2.1.1.2 PLASTIC INJECTABLE DEVICES 6.2.1.2.1 FILLABLE SYRINGES 6.2.1.2.2 PREFILLED SYRINGES 6.2.1.3.1 REUSABLE INJECTION DEVICES 6.2.1.3.2 DISPOSABLE INJECTION DEVICES 6.2.2 SELF-INJECTION DEVICES 6.2.2.1 NEEDLE-FREE INJECTORS 6.2.2.4 WEARABLE INJECTORS 6.2.2.4.1 INCREASING NEED FOR SAFE AND CONVENIENT INJECTIONS TO ACCELERATE GROWTH 6.2.2.5 OTHER SELF-INJECTION DEVICES 6.3.1 CONVENTIONAL DRUG DELIVERY FORMULATIONS 6.3.1.1.1 HIGH STABILITY AND STERILITY BENEFITS TO INTENSIFY GROWTH 6.3.1.2 RECONSTITUTED/LYOPHILIZED FORMULATIONS 6.3.1.2.1 HIGHER SUITABILITY FOR PARENTERAL ADMINISTRATION TO AID GROWTH 6.3.1.3.1 INNOVATIONS IN INJECTABLE SUSPENSIONS FOR STABLE AND SUSTAINED DELIVERY TO AID GROWTH 6.3.1.4.1 ADVANCEMENTS IN INJECTABLE EMULSIONS FOR CONTROLLED AND SUSTAINED DRUG DELIVERY TO DRIVE MARKET 6.3.2 NOVEL DRUG DELIVERY FORMULATIONS 6.3.2.1 COLLOIDAL DISPERSIONS 6.3.2.1.3 POLYMERIC/MIXED MICELLES 6.3.3 LONG-ACTING INJECTABLE FORMULATIONS 6.3.3.1 DECREASED SIDE EFFECTS AND OVERALL MEDICAL COST REDUCTION TO ADVANCE GROWTH 7 INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING Market Size & Growth Rate Forecast Analysis to 2030 in USD Billion | 5 Data Tables 287 7.2.1 EASE OF TRANSPORTATION AND LOW MANUFACTURING COST TO AID GROWTH 7.3.1 NEED FOR SECURE, DEPENDABLE, AND COST-EFFECTIVE CONTAINERS TO ENCOURAGE GROWTH 7.4.1 INCREASING FOCUS ON DOSE ACCURACY AND PATIENT CONVENIENCE TO FACILITATE GROWTH 7.5.1 RISING FOCUS ON SAFE STORAGE OF SOLUTIONS AND EMULSIONS TO FOSTER GROWTH 8 INJECTABLE DRUG DELIVERY, BY THERAPEUTIC APPLICATION Market Size & Growth Rate Forecast Analysis to 2030 in USD Billion | 47 Data Tables 296 8.2.1 RHEUMATOID ARTHRITIS 8.2.1.1 INCREASED FOCUS ON EARLY-STAGE DIAGNOSIS AND TREATMENT TO AMPLIFY GROWTH 8.2.2.1 INCREASING TARGET PATIENT POOL TO CONTRIBUTE TO GROWTH 8.2.3.1 RISING USE OF LIPOSOMES TO AID GROWTH 8.2.4.1 LIFESTYLE CHANGES AND HIGH DISEASE PREVALENCE TO SUPPORT GROWTH 8.2.5 OTHER AUTOIMMUNE DISEASES 8.3.1.1 GROWING PREFERENCE FOR SELF-INJECTION DEVICES OVER TRADITIONAL SYRINGES TO DRIVE MARKET 8.3.2 REPRODUCTIVE HEALTH DISEASES 8.3.2.1 LACK OF HEALTHCARE FACILITIES AND HYGIENE PRACTICES TO AID GROWTH 8.3.3 ANTITHROMBOTIC/THROMBOLYTIC THERAPY 8.3.3.1 HIGH EFFICACY AND SAFETY OF HEPARIN FOR ANTITHROMBOTIC THERAPY TO AID GROWTH 8.3.4.1 INCREASING NUMBER OF WOMEN WITH CALCIUM AND VITAMIN D DEFICIENCIES TO FOSTER GROWTH 8.3.5 GROWTH HORMONE DEFICIENCY 8.3.5.1 INCREASED NEED FOR DAILY INJECTIONS OF RECOMBINANT HUMAN GROWTH HORMONES TO FUEL MARKET 8.4.1 CHANGING SEDENTARY LIFESTYLE AND CONSUMPTION OF OVER-PROCESSED FOODS TO AID GROWTH 8.5.1 INCREASING LAUNCHES OF NEW VACCINES AND TARGETED THERAPIES TO BOLSTER GROWTH 8.6.1 GROWING ADVANCEMENTS IN INJECTABLE THERAPIES TO DRIVE MARKET 8.7.1 FAVORABLE GOVERNMENT INITIATIVES TO AUGMENT GROWTH 8.8 OTHER THERAPEUTIC APPLICATIONS 8.8.1.1 GROWING FOCUS ON TREATING CHRONIC PAIN TO DRIVE MARKET 8.8.2.1 INCREASING PREVALENCE OF ASTHMA AND ECZEMA TO PROMOTE GROWTH 8.8.3 AESTHETIC TREATMENTS 8.8.3.1 GROWING POPULARITY OF AESTHETIC PROCEDURES TO PROPEL MARKET 8.8.4.1 NEED TO CURB VIRUS SPREAD DUE TO NEEDLE RESHARE TO SUSTAIN GROWTH 8.8.5.1 INCREASING NEED FOR PREVENTIVE TREATMENT PLANS TO ASSIST GROWTH 9 INJECTABLE DRUG DELIVERY, BY USAGE PATTERN Market Size & Growth Rate Forecast Analysis to 2030 in USD Billion | 4 Data Tables 345 9.2.1 RISE IN INFECTIOUS DISEASES TO ACCELERATE GROWTH 9.3.1 GROWING DEMAND FOR VACCINES FROM HEALTHCARE ORGANIZATIONS TO DRIVE MARKET 10 INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION Market Size & Growth Rate Forecast Analysis to 2030 in USD Billion | 9 Data Tables 352 10.2 DERMAL-BASED ADMINISTRATION 10.2.1 RAPID AND EFFECTIVE METHOD WITH LOW PAIN TO AMPLIFY GROWTH 10.3 CIRCULATORY/MUSCULOSKELETAL SYSTEM-BASED ADMINISTRATION 10.3.1 HIGH PREFERENCE FOR EMERGENCY CARE TO SUPPORT GROWTH 10.4 ORGAN-BASED ADMINISTRATION 10.4.1 GROWING UTILIZATION OF INTRAVITREAL AND INTRA-OCULAR INJECTIONS IN COMPLEX PROCEDURES TO BOOST MARKET 10.5 CENTRAL NERVOUS SYSTEM-BASED ADMINISTRATION 10.5.1 INCREASING FOCUS ON PAIN MANAGEMENT TO PROMOTE GROWTH 11 INJECTABLE DRUG DELIVERY MARKET, BY END USER Market Size & Growth Rate Forecast Analysis to 2030 in USD Billion | 6 Data Tables 363 11.2.1 RISING INCIDENCE OF CHRONIC DISEASES TO AUGMENT GROWTH 11.3.1 GROWING TREND OF SELF-ADMINISTRATION TO PROPEL MARKET 11.4 LONG-TERM CARE SETTINGS 11.4.1 BOOMING ELDERLY POPULATION AND BURDEN OF CHRONIC DISEASES TO EXPEDITE GROWTH 11.5.1 GLOBAL SHIFT TOWARD AGED POPULATION TO STIMULATE GROWTH 12 INJECTABLE DRUG DELIVERY MARKET, BY REGION Comprehensive coverage of 8 Regions with country-level deep-dive of 20 Countries | 926 Data Tables
Steps to Take Before Scheduling Your Donation Contact your prescribing provider firstbefore calling your blood bankto discuss your GLP-1 therapy, dosing schedule, and any underlying conditions
